| Obesity |
1 |
1 |
| Heart Failure (HF) |
0 |
0.9 |
| Heart |
0 |
0.65 |
| Weight Loss |
0 |
0.65 |
| Cardiovascular Risk Management |
0 |
0.57 |
| Weight Management |
0 |
0.47 |
| Cardiomyopathy |
0 |
0.37 |
| Cardiovascular Imaging |
0 |
0.31 |
| GLP-1 Receptor Agonist |
0 |
0.24 |
| Type 2 Diabetes Mellitus |
0 |
0.2 |
| Body Mass Index |
0 |
0.14 |
| Cardiovascular disease |
0 |
0.14 |
| Kansas |
0 |
0.14 |
| Receptors |
0 |
0.14 |
| Clinical Research |
0 |
0.09 |
| Insurance |
0 |
0.09 |
| SGLT2 Inhibitor |
0 |
0.09 |
| Washington |
0 |
0.09 |
| B-Type Natriuretic Peptide |
0 |
0.07 |
| Healthcare and Medical Technology |
0 |
0.07 |
| Revenue and Practice Management |
0 |
0.07 |